Literature DB >> 7528468

Utility of cytokeratin immunostaining in separating pulmonary adenocarcinomas from colonic adenocarcinomas.

T S Loy1, R D Calaluce.   

Abstract

Adenocarcinomas of uncertain origin are a frequent problem for surgical pathologists. To determine the utility of immunostaining for cytokeratin 7 and cytokeratin 20 in the separation of pulmonary adenocarcinomas from colonic adenocarcinomas, we studied routinely processed, formalin-fixed tissue from 151 of these tumors using commercially available monoclonal antibodies and an avidin-biotin immunohistochemical technique. Used alone, neither cytokeratin 7 immunostaining or cytokeratin 20 immunostaining reliably separated these tumors. However, the immunophenotype of cytokeratin 7 positive/cytokeratin 20 negative was seen in 86% of the pulmonary adenocarcinomas, and in 0% of the colonic adenocarcinomas. Conversely, the cytokeratin 7-negative/cytokeratin 20-positive immunophenotype was seen in 77% of the colonic carcinomas, and in 0% of the pulmonary tumors. In conclusion, cytokeratin 7/cytokeratin 20 immunostaining patterns may be helpful in separating pulmonary adenocarcinomas from colonic adenocarcinomas.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7528468     DOI: 10.1093/ajcp/102.6.764

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  17 in total

1.  Metastatic chest wall tumor suspected to be of lung origin by immunoreactivity for cytokeratin 7 and 20.

Authors:  Shuji Haraguchi; Masafumi Hioki; Mina Takushima; Kunio Yanagimoto; Kiyoshi Koizumi; Kazuo Shimizu
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2006-03

2.  Cytokeratin CK 7 and CK 20 expression in pituitary adenomas.

Authors:  Stephen W Coons; Sarah I Estrada; Ruben Gamez; William L White
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

3.  The limited difference between keratin patterns of squamous cell carcinomas and adenocarcinomas is explicable by both cell lineage and state of differentiation of tumour cells.

Authors:  E B van Dorst; G N van Muijen; S V Litvinov; G J Fleuren
Journal:  J Clin Pathol       Date:  1998-09       Impact factor: 3.411

4.  Non-small cell lung cancer with distal cutaneous metastases in a patient with a previously treated colorectal carcinoma.

Authors:  D Thurston; T Hossain; N Waraich; A Shukla
Journal:  Ann R Coll Surg Engl       Date:  2016-03       Impact factor: 1.891

5.  Anti-cytokeratin 7: a positive marker for epithelial dysplasia in flat bowel mucosa.

Authors:  Svjetlana Radović; Ivan Selak; Mirsad Babić; Zora Vukobrat-Bijedić; Zeljka Knezević
Journal:  Bosn J Basic Med Sci       Date:  2004-07       Impact factor: 3.363

6.  Challenging diagnosis of a jejunal adenocarcinoma with ovarian metastasis: report of an unusual case.

Authors:  Yang Yang Huang; Jeremy John Pratt; Marcus Dabner; William Tjhin
Journal:  BMJ Case Rep       Date:  2013-04-10

7.  Long-term survival after incomplete resection of immunohistochemically diagnosed T0N1 lung cancer: report of a case.

Authors:  Yotaro Izumi; Makio Mukai; Koji Kikuchi; Koichi Kobayashi
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

8.  The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibody.

Authors:  Reyhan Bayrak; Hacer Haltas; Sibel Yenidunya
Journal:  Diagn Pathol       Date:  2012-01-23       Impact factor: 2.644

9.  Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report.

Authors:  Martin F Sprinzl; Carl C Schimanski; Markus Moehler; Simin Schadmand-Fischer; Peter R Galle; Stephan Kanzler
Journal:  BMC Cancer       Date:  2006-07-17       Impact factor: 4.430

10.  Cytokeratin 7 and 20 staining for the diagnosis of lung and colorectal adenocarcinoma.

Authors:  S Kummar; M Fogarasi; A Canova; A Mota; T Ciesielski
Journal:  Br J Cancer       Date:  2002-06-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.